Non-major-histocompatibility-complex genetics of ankylosing spondylitis

Best Practice and Research: Clinical Rheumatology

Volumn 20, Issue 3, 2006, Pages 611-621

  Brown, Matthew A ^a  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

ankylosing spondylitis; association; genetics; interleukin 1 gene complex; linkage

Indexed keywords

ALPHA 1 ANTITRYPSIN; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CD14 ANTIGEN; CYTOCHROME P450 2D6; DEBRISOQUINE 4 HYDROXYLASE; HLA B27 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; MAJOR HISTOCOMPATIBILITY ANTIGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TYROSINE PHOSPHATASE; STROMELYSIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ASIAN; CAUCASIAN; CHROMOSOME 2; CLINICAL FEATURE; DRUG TARGETING; FAMILY STUDY; GENE IDENTIFICATION; GENE LINKAGE DISEQUILIBRIUM; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC DATABASE; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HERITABILITY; HUMAN; HYPOTHESIS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TWINS; VARIABLE NUMBER OF TANDEM REPEAT;

ASIAN CONTINENTAL ANCESTRY GROUP; CYTOCHROME P-450 CYP2D6; EUROPEAN CONTINENTAL ANCESTRY GROUP; FAMILY HEALTH; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HLA-B27 ANTIGEN; HUMANS; INTERLEUKIN-1; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LINKAGE (GENETICS); MAJOR HISTOCOMPATIBILITY COMPLEX; NOD2 SIGNALING ADAPTOR PROTEIN; PHOSPHATE TRANSPORT PROTEINS; PROTEINS; SPONDYLITIS, ANKYLOSING; TRANSFORMING GROWTH FACTOR BETA; TWIN STUDIES;

EID: 33744899333     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2006.03.005     Document Type: Review

References (83)

1. Braun J., Bollow M., Remlinger G., et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis and Rheumatism 41 (1998) 58-67
2. van der Linden S., Valkenburg H., and Cats A. The risk of developing ankylosing spondylitis in HLA-B27 positive individuals: a family and population study. Br J Rheumatol 22 supplement 2 (1983) 18-19
3. Calin A., Marder A., Becks E., et al. Genetic differences between B27 positive patients with ankylosing spondylitis and B27 positive healthy controls. Arthritis and Rheumatism 26 (1983) 1460-1464
4. Brown M.A., Kennedy L.G., MacGregor A.J., et al. Susceptibility to ankylosing spondylitis in twins: the role of genes, HLA, and the environment. Arthritis and Rheumatism 40 (1997) 1823-1828
5. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. American Journal of Human Genetics 46 (1990) 222-228
6. Brown M.A., Laval S.H., Brophy S., et al. Recurrence risk modelling of the genetic susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases 59 (2000) 883-886
7. Hamersma J., Cardon L.R., Bradbury L., et al. Is disease severity in ankylosing spondylitis genetically determined?. Arthritis and Rheumatism 44 (2001) 1396-1400
8. Brophy S., Hickey S., Menon A., et al. Concordance of disease severity among family members with ankylosing spondylitis?. The Journal of Rheumatology 31 (2004) 1775-1778
9. Szabo Z., Szanto S., Vegvari A., et al. Genetic control of experimental spondylarthropathy. Arthritis and Rheumatism 52 (2005) 2452-2460
10. Laval S.H., Timms A., Edwards S., et al. Whole-genome screening in ankylosing spondylitis: evidence of non-MHC genetic-susceptibility loci. American Journal of Human Genetics 68 (2001) 918-926
11. Brown M.A., Pile K.D., Kennedy L.G., et al. A genome-wide screen for susceptibility loci in ankylosing spondylitis. Arthritis and Rheumatism 41 (1998) 588-595
12. Zhang G., Luo J., Bruckel J., et al. Genetic studies in familial ankylosing spondylitis susceptibility. Arthritis and Rheumatism 50 (2004) 2246-2254
13. Miceli-Richard C., Zouali H., Said-Nahal R., et al. Significant linkage to spondyloarthropathy on 9q31-34. Human Molecular Genetics 13 (2004) 1641-1648
14. Carter KW, Pluzhnikov A, Timms AE, et al. Meta-analysis in ankylosing spondylitis (AS)-genomewide linkage map including 589 affected sibling pairs. Arthritis and Rheumatism; submitted for publication.
15. Brown MA, Brophy S, Bradbury L, et al. Identification of major loci controlling clinical manifestations of ankylosing spondylitis. Arthritis and Rheumatism; submitted for publication.
16. van der Paardt M., Crusius J.B., Garcia-Gonzalez M.A., et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford, England) 41 (2002) 1419-1423
17. McGarry F., Neilly J., Anderson N., et al. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology (Oxford, England) 40 (2001) 1359-1364
18. Danis V.A., Millington M., Hyland V.J., et al. Cytokine production by normal human monocytes: inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clinical and Experimental Immunology 99 (1995) 303-310
19. Hurme M., and Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. European Journal of Immunology 28 (1998) 2598-2602
20. Kim T.H., Stone M.A., Rahman P., et al. Interleukin 1 and nuclear factor-kappaB polymorphisms in ankylosing spondylitis in Canada and Korea. The Journal of Rheumatology 32 (2005) 1907-1910
21. Djouadi K., Nedelec B., Tamouza R., et al. Interleukin 1 gene cluster polymorphisms in multiplex families with spondylarthropathies. Cytokine 13 (2001) 98-103
22. Jin L., Zhang G., Akey J.M., et al. Lack of linkage of IL1RN genotypes with ankylosing spondylitis susceptibility. Arthritis and Rheumatism 50 (2004) 3047-3048
23. Timms A.E., Crane A.M., Sims A.M., et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. American Journal of Human Genetics 75 (2004) 587-595
24. Chou C-T, Timms AE, Wei JC, et al. Replication of association of IL-1 gene complex members with ankylosing spondylitis in Taiwanese Chinese. Annals of the Rheumatic Diseases; in press.
25. Maksymowych W.P., Reeve J.P., Reveille J.D., et al. High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. Arthritis and Rheumatism 48 (2003) 2011-2018
26. Sims A.M., Timms A., Pointon J.J., et al. Fine-mapping of the IL-1 gene cluster pinpoints genetic associations with ankylosing spondylitis. Arthritis and Rheumatism 59 (2005) 576
27. Albuquerque S., Zhang G., Zhou X., et al. Association of IL-1 genes with ankylosing spondylitis susceptibility. Evidence from family-based analyses. Arthritis and Rheumatism 52 (2005) F35/529
28. Ravindran J.S., Owen P., Lagan A., et al. Interleukin 1alpha, interleukin 1beta and interleukin 1 receptor gene polymorphisms in psoriatic arthritis. Rheumatology (Oxford, England) 43 (2004) 22-26
29. Rahman P., Peddle L., Sun S., et al. IL-1 locus on chromosome 2q confers susceptibility on psoriatic arthritis. Arthritis and Rheumatism 52 (2005) S692
30. Haibel H., Rudwaleit M., Listing J., et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Annals of the Rheumatic Diseases 64 (2005) 296-298
31. Tan A.L., Marzo-Ortega H., O'Connor P., et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Annals of the Rheumatic Diseases 63 (2004) 1041-1045
32. Beyeler C., Armstrong M., Bird H.A., et al. Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis. Annals of the Rheumatic Diseases 55 (1996) 66-68
33. Brown M.A., Edwards S., Hoyle E., et al. Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Human Molecular Genetics 9 (2000) 1563-1566
34. Hugot J.P., Chamaillard M., Zouali H., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411 (2001) 599-603
35. Ogura Y., Bonen D.K., Inohara N., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411 (2001) 603-606
36. Crane A.M., Bradbury L., van Heel D.A., et al. Role of NOD2 variants in spondylarthritis. Arthritis and Rheumatism 46 (2002) 1629-1633
37. Miceli-Richard C., Zouali H., Lesage S., et al. CARD15/NOD2 analyses in spondylarthropathy. Arthritis and Rheumatism 46 (2002) 1405-1406
38. Ferreiros-Vidal I., Amarelo J., Barros F., et al. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. The Journal of Rheumatology 30 (2003) 102-104
39. D'Amato M. The Crohn's associated NOD2 3020InsC frameshift mutation does not confer susceptibility to ankylosing spondylitis. The Journal of Rheumatology 29 (2002) 2470-2471
40. Kim T.H., Rahman P., Jun J.B., et al. Analysis of CARD15 polymorphisms in Korean patients with ankylosing spondylitis reveals absence of common variants seen in Western populations. The Journal of Rheumatology 31 (2004) 1959-1961
41. Mielants H., Veys E.M., Cuvelier C., et al. Macroscopic and histological changes of the ileum HLA-B27 related diseases: therapeutic consequences. International Journal of Clinical Research 4 (1984) 409-414
42. Archer J.R. Ankylosing spondylitis, IgA, and transforming growth factors. Annals of the Rheumatic Diseases 54 (1995) 544-546
43. McGarry F., Cousins L., Sturrock R.D., et al. A polymorphism within the transforming growth factor beta 1 gene is associated with ankylosing spondylitis (AS). Rheumatology (Oxford, England) 41 supplement 1 (2001) 16
44. Jaakkola E., Crane A.M., Laiho K., et al. The effect of transforming growth factor (beta)1 gene polymorphisms in ankylosing spondylitis. Rheumatology (Oxford, England) (2003) 32-38
45. van der Paardt M., Crusius J.B., Garcia-Gonzalez M.A., et al. Susceptibility to ankylosing spondylitis: no evidence for the involvement of transforming growth factor beta 1 (TGFB1) gene polymorphisms. Annals of the Rheumatic Diseases 64 (2005) 616-619
46. Howe H.S., Cheung P.L., Kong K.O., et al. Transforming growth factor beta-1 and gene polymorphisms in oriental ankylosing spondylitis. Rheumatology (Oxford, England) 44 (2005) 51-54
47. Sampson H.W. Spondyloarthropathy in progressive ankylosis (ank/ank) mice: morphological features. Spine 13 (1988) 645-649
48. Krug H.E., Wietgrefe M.M., Ytterberg S.R., et al. Murine progressive ankylosis is not immunologically mediated. The Journal of Rheumatology 24 (1997) 115-122
49. Krug H.E., and Taurog J.D. HLA-B27 has no effect on the phenotypic expression of progressive ankylosis in ank/ank mice. The Journal of Rheumatology 27 (2000) 1257-1259
50. Tsui F.W., Tsui H.W., Cheng E.Y., et al. Novel genetic markers in the 5'-flanking region of ANKH are associated with ankylosing spondylitis. Arthritis and Rheumatism 48 (2003) 791-797
51. Timms A.E., Zhang Y., Bradbury L., et al. Investigation of the role of ANKH in ankylosing spondylitis. Arthritis and Rheumatism 48 (2003) 2898-2902
52. Brown M.A., Rudwaleit M., Pile K.D., et al. The role of germline polymorphisms in the T-cell receptor in susceptibility to ankylosing spondylitis. British Journal of Rheumatology 37 (1998) 454-458
53. Eskdale J., Gallagher G., Verweij C.L., et al. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proceedings of the National Academy of Sciences United States of America 95 (1998) 9465-9470
54. Rudwaleit M., Siegert S., Yin Z., et al. Low T cell production of TNFalpha and IFNgamma in ankylosing spondylitis: its relation to HLA-B27 and influence of the TNF-308 gene polymorphism. Annals of the Rheumatic Diseases 60 (2001) 36-42
55. Kaluza W., Leirisalo-Repo M., Marker-Hermann E., et al. IL10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients. Arthritis and Rheumatism 44 (2001) 1209-1214
56. Goedecke V., Crane A.M., Jaakkola E., et al. Interleukin 10 polymorphisms in ankylosing spondylitis. Genes and Immunity 4 (2003) 74-76
57. Vazquez-Del M.M., Garcia-Gonzalez A., Munoz-Valle J.F., et al. Interleukin 1beta (IL-1beta), IL-10, tumor necrosis factor-alpha, and cellular proliferation index in peripheral blood mononuclear cells in patients with ankylosing spondylitis. The Journal of Rheumatology 29 (2002) 522-526
58. Gratacos J., Collado A., Filella X., et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity. British Journal of Rheumatology 33 (1994) 927-931
59. Collado-Escobar M.D., Nieto A., Mataran L., et al. Interleukin 6 gene promoter polymorphism is not associated with ankylosing spondylitis. The Journal of Rheumatology 27 (2000) 1461-1463
60. van der Paardt M., Crusius J.B., de Koning M.H., et al. No evidence for involvement of the Toll-like receptor 4 (TLR4) A896G and CD14-C260T polymorphisms in susceptibility to ankylosing spondylitis. Annals of the Rheumatic Diseases 64 (2005) 235-238
61. Jin L., Weisman M., Zhang G., et al. Lack of association of matrix metalloproteinase 3 (MMP3) genotypes with ankylosing spondylitis susceptibility and severity. Rheumatology (Oxford, England) 44 (2005) 55-60
62. Orozco G., Garcia-Porrua C., Lopez-Nevot M.A., et al. Lack of association between ankylosing spondylitis and a functional polymorphism of PTPN22 proposed as a general susceptibility marker for autoimmunity. Annals of the Rheumatic Diseases (2005)
63. Sierakowski S., Chwiecko J., and Kita K. Alpha-1-antitrypsin phenotypes in patients with ankylosing spondylitis. Roczniki Akademii Medycznej w Bialymstoku 46 (2001) 54-59
64. Buisseret P.D., Pembrey M.E., and Lessof M.H. alpha 1-antitrypsin phenotypes in rheumatoid arthritis and ankylosing spondylitis. Lancet 2 (1977) 1358-1359
65. Moller P., and Fagerhol M.K. Pi phenotypes in patients with ankylosing spondylitis, acute anterior uveitis, psoriasis and chronic prostatitis. Clinical Genetics 26 (1984) 339-341
66. Pal A., Hill M., Wordsworth P., et al. Secretor status and ankylosing spondylitis. The Journal of Rheumatology 25 (1998) 318-319
67. Smith G.W., James V., Mackenzie D.A., et al. Ankylosing spondylitis and secretor status: a re-evaluation. British Journal of Rheumatology 36 (1997) 778-780
68. Shinebaum R. ABO blood group and secretor status in the spondyloarthropathies. FEMS Microbiology and Immunology 1 (1989) 389-395
69. Linssen A., Rothova A., Broekema N., et al. Genes on chromosome 14q and their role in the pathogenesis of HLA-B27 associated diseases. Clinical and Experimental Rheumatology 5 supplement 1 (1987) S89-S95
70. Broekema N., Linssen A., Luyendijk L., et al. Association of Gm allotypes with the occurrence of ankylosing spondylitis in HLA-B27-positive anterior uveitis. American Journal of Ophthalmology 102 (1986) 549
71. Kijlstra A., Linssen A., and Ockhuizen T. Association of Gm allotypes with the occurrence of ankylosing spondylitis in HLA-B27-positive anterior uveitis. American Journal of Ophthalmology 98 (1984) 732-735
72. Gran J.T., Teisberg P., Olaissen B., et al. HLA-B27 and allotypes of complement components in ankylosing spondylitis. The Journal of Rheumatology 11 (1984) 324-326
73. Demaine A.G., Panayi G.S., Vaughan R.W., et al. Immunoglobulin allotypes in psoriasis, psoriatic arthropathy and ankylosing spondylitis. Experimental and Clinical Immunogenetics 1 (1984) 61-65
74. Mierau R., von Muhlen C.A., Zarnowski H., et al. Immunoglobulin allotype Gm(1,2; 21) in ankylosing spondylitis with peripheral arthritis. Annals of the Rheumatic Diseases 47 (1988) 893-897
75. Seo J.S., Lee S.S., Kim S.I., et al. Influence of VEGF gene polymorphisms on the severity of ankylosing spondylitis. Rheumatology (Oxford, England) 44 (2005) 1299-1302
76. Styrkarsdottir U., Cazier J.B., Kong A., et al. Linkage of osteoporosis to chromosome 20p12 and association to BMP2. PLoS Biology 1 (2003) E69
77. Allen M., Heinzmann A., Noguchi E., et al. Positional cloning of a novel gene influencing asthma from chromosome 2q14. Nature Genetics 35 (2003) 258-263
78. Helgadottir A., Manolescu A., Thorleifsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nature Genetics 36 (2004) 233-239
79. Risch N., and Merikangas K. The future of genetic studies of complex human diseases. Science 273 (1996) 1516-1517
80. Risch N.J. Searching for genetic determinants in the new millennium. Nature 405 (2000) 847-856
81. Botstein D., and Risch N. Discovering genotypes underlying human phenotypes: past successes for Mendelian disease, future approaches for complex diseases. Nature Genetics 33 supplement (2003) 228-237
82. Suzuki A., Yamada R., Chang X., et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nature Genetics 34 (2003) 395-402
83. Begovich A.B., Carlton V.E., Honigberg L.A., et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. American Journal of Human Genetics 75 (2004) 330-337